Cargando…
Cell-free fetal DNA testing and its correlation with prenatal indications
BACKGROUND: The prenatal test of cell-free fetal DNA (cffDNA) is also known as noninvasive prenatal testing (NIPT) with high sensitivity and specificity. This study is to evaluate the performance of NIPT and its clinical relevance with various clinical indications. METHODS: A retrospective analysis...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385810/ https://www.ncbi.nlm.nih.gov/pubmed/34429082 http://dx.doi.org/10.1186/s12884-021-04044-5 |
_version_ | 1783742164431273984 |
---|---|
author | Wang, Jing-wei Lyu, Yong-nan Qiao, Bin Li, Yan Zhang, Yan Dhanyamraju, Pavan Kumar Bamme, Yevgeniya Yu, Michael D. Yang, Dongqin Tong, Yong-qing |
author_facet | Wang, Jing-wei Lyu, Yong-nan Qiao, Bin Li, Yan Zhang, Yan Dhanyamraju, Pavan Kumar Bamme, Yevgeniya Yu, Michael D. Yang, Dongqin Tong, Yong-qing |
author_sort | Wang, Jing-wei |
collection | PubMed |
description | BACKGROUND: The prenatal test of cell-free fetal DNA (cffDNA) is also known as noninvasive prenatal testing (NIPT) with high sensitivity and specificity. This study is to evaluate the performance of NIPT and its clinical relevance with various clinical indications. METHODS: A retrospective analysis was conducted on 14,316 pregnant women with prenatal indications, including advanced maternal age (≥35 years), maternal serum screening abnormalities, the thickened nuchal translucency (≥2.5 mm) and other ultrasound abnormalities, twin pregnancy/IVF-ET pregnancy, etc. The whole-genome sequencing (WGS) of maternal plasma cffDNA was employed in this study. RESULTS: A total of 189 (1.32%) positive NIPT cases were identified, and 113/189 (59.79%)cases were confirmed by invasive prenatal testing. Abnormal serological screening (53.14%) was the most common indication, followed by elderly pregnancy (23.02%). The positive prediction value for T21, T18, T13, sex chromosome abnormalities, other autosomal aneuploidy abnormalities, and CNV abnormalities were 91.84, 68.75,37.50, 66.67, 14.29, and 6.45%, respectively. The positive rate and the true positive rate of nuchal translucency (NT) thickening were the highest (4.17 and 3.33%), followed by the voluntary requirement group (3.49 and 1.90%) in the various prenatal screening indications. The cffDNA concentration was linearly correlated with gestational age (≥10 weeks) and the positive NIPT group’s Z-score values. CONCLUSIONS: whole-genome sequencing of cffDNA has extremely high sensitivity and specificity for T21, high sensitivity for T18, sex chromosome abnormalities, and T13. It also provides evidence for other abnormal chromosomal karyotypes (CNV and non-21/18/13 autosomal aneuploidy abnormalities). The cffDNA concentration is closely related to the gestational age and determines the specificity of NIPT. Our results highlight NIPT’s clinical significance, which is an effective prenatal screening tool for high-quality care of pregnancy. |
format | Online Article Text |
id | pubmed-8385810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83858102021-08-25 Cell-free fetal DNA testing and its correlation with prenatal indications Wang, Jing-wei Lyu, Yong-nan Qiao, Bin Li, Yan Zhang, Yan Dhanyamraju, Pavan Kumar Bamme, Yevgeniya Yu, Michael D. Yang, Dongqin Tong, Yong-qing BMC Pregnancy Childbirth Research Article BACKGROUND: The prenatal test of cell-free fetal DNA (cffDNA) is also known as noninvasive prenatal testing (NIPT) with high sensitivity and specificity. This study is to evaluate the performance of NIPT and its clinical relevance with various clinical indications. METHODS: A retrospective analysis was conducted on 14,316 pregnant women with prenatal indications, including advanced maternal age (≥35 years), maternal serum screening abnormalities, the thickened nuchal translucency (≥2.5 mm) and other ultrasound abnormalities, twin pregnancy/IVF-ET pregnancy, etc. The whole-genome sequencing (WGS) of maternal plasma cffDNA was employed in this study. RESULTS: A total of 189 (1.32%) positive NIPT cases were identified, and 113/189 (59.79%)cases were confirmed by invasive prenatal testing. Abnormal serological screening (53.14%) was the most common indication, followed by elderly pregnancy (23.02%). The positive prediction value for T21, T18, T13, sex chromosome abnormalities, other autosomal aneuploidy abnormalities, and CNV abnormalities were 91.84, 68.75,37.50, 66.67, 14.29, and 6.45%, respectively. The positive rate and the true positive rate of nuchal translucency (NT) thickening were the highest (4.17 and 3.33%), followed by the voluntary requirement group (3.49 and 1.90%) in the various prenatal screening indications. The cffDNA concentration was linearly correlated with gestational age (≥10 weeks) and the positive NIPT group’s Z-score values. CONCLUSIONS: whole-genome sequencing of cffDNA has extremely high sensitivity and specificity for T21, high sensitivity for T18, sex chromosome abnormalities, and T13. It also provides evidence for other abnormal chromosomal karyotypes (CNV and non-21/18/13 autosomal aneuploidy abnormalities). The cffDNA concentration is closely related to the gestational age and determines the specificity of NIPT. Our results highlight NIPT’s clinical significance, which is an effective prenatal screening tool for high-quality care of pregnancy. BioMed Central 2021-08-24 /pmc/articles/PMC8385810/ /pubmed/34429082 http://dx.doi.org/10.1186/s12884-021-04044-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Wang, Jing-wei Lyu, Yong-nan Qiao, Bin Li, Yan Zhang, Yan Dhanyamraju, Pavan Kumar Bamme, Yevgeniya Yu, Michael D. Yang, Dongqin Tong, Yong-qing Cell-free fetal DNA testing and its correlation with prenatal indications |
title | Cell-free fetal DNA testing and its correlation with prenatal indications |
title_full | Cell-free fetal DNA testing and its correlation with prenatal indications |
title_fullStr | Cell-free fetal DNA testing and its correlation with prenatal indications |
title_full_unstemmed | Cell-free fetal DNA testing and its correlation with prenatal indications |
title_short | Cell-free fetal DNA testing and its correlation with prenatal indications |
title_sort | cell-free fetal dna testing and its correlation with prenatal indications |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385810/ https://www.ncbi.nlm.nih.gov/pubmed/34429082 http://dx.doi.org/10.1186/s12884-021-04044-5 |
work_keys_str_mv | AT wangjingwei cellfreefetaldnatestinganditscorrelationwithprenatalindications AT lyuyongnan cellfreefetaldnatestinganditscorrelationwithprenatalindications AT qiaobin cellfreefetaldnatestinganditscorrelationwithprenatalindications AT liyan cellfreefetaldnatestinganditscorrelationwithprenatalindications AT zhangyan cellfreefetaldnatestinganditscorrelationwithprenatalindications AT dhanyamrajupavankumar cellfreefetaldnatestinganditscorrelationwithprenatalindications AT bammeyevgeniya cellfreefetaldnatestinganditscorrelationwithprenatalindications AT yumichaeld cellfreefetaldnatestinganditscorrelationwithprenatalindications AT yangdongqin cellfreefetaldnatestinganditscorrelationwithprenatalindications AT tongyongqing cellfreefetaldnatestinganditscorrelationwithprenatalindications |